Viskase Holdings, INC. (ENZN) — SEC Filings

Overview

Viskase Holdings, INC. (ENZN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 26, 2026: Viskase Holdings, Inc. filed an 8-K on March 26, 2026, reporting the completion of an acquisition or disposition of assets. The filing also disclosed unregistered sales of equity securities, changes in control, and changes related to officers and directors. Amendments to articles of incorporation or

Sentiment Summary

Across 30 filings, the sentiment breakdown is: 2 bearish, 28 neutral. The dominant filing sentiment for Viskase Holdings, INC. is neutral.

Filing Type Overview

Viskase Holdings, INC. (ENZN) has filed 2 425, 14 8-K, 1 8-A12G/A, 6 10-Q, 2 10-K/A, 2 10-K, 1 SC 13D/A, 1 DEF 14A, 1 8-K/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (30)

• Viskase Holdings Reports Asset Deal, Equity Sales, Control Changes — 8-K · Mar 26, 2026 Risk: medium
  Viskase Holdings, Inc. filed an 8-K on March 26, 2026, reporting the completion of an acquisition or disposition of assets. The filing also disclosed unregister
• ENZON PHARMACEUTICALS Files 425 for Business Combination — 425 · Mar 25, 2026
  This 425 filing from ENZON PHARMACEUTICALS, INC. (CIK: 0000727510) on March 25, 2026, is a communication related to a business combination. While the filing its
• ENZON PHARMACEUTICALS Files 8-K: Regulation FD Disclosure — 8-K · Mar 25, 2026
  ENZON PHARMACEUTICALS, INC. filed an 8-K on March 25, 2026, under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This f
• ENZON PHARMACEUTICALS Amends Securities Registration (8-A12G/A) — 8-A12G/A · Mar 24, 2026
  ENZON PHARMACEUTICALS, INC. (CIK: 0000727510) filed an amended Form 8-A12G/A on March 24, 2026, to register its securities under Section 12(g) of the Securities
• ENZON PHARMACEUTICALS Files 425 for Business Combination — 425 · Mar 24, 2026
  This 425 filing from ENZON PHARMACEUTICALS, INC. (CIK: 0000727510) on March 24, 2026, indicates a communication related to a business combination. While the spe
• 8-K Filing — 8-K · Dec 23, 2025
• Enzon's Losses Mount Amid Zero Revenue, Viskase Merger Costs — 10-Q · Nov 12, 2025 Risk: high
  Enzon Pharmaceuticals, Inc. (ENZN) reported a net loss of $824,000 for the three months ended September 30, 2025, a significant increase from the net income of
• Enzon Pharmaceuticals Files 8-K for Material Agreement — 8-K · Oct 24, 2025 Risk: medium
  Enzon Pharmaceuticals, Inc. filed an 8-K on October 24, 2025, reporting a material definitive agreement. The filing also includes Regulation FD disclosures and
• Enzon Pharmaceuticals Files 8-K: Material Agreement & Security Holder Updates — 8-K · Sep 30, 2025 Risk: medium
  Enzon Pharmaceuticals, Inc. filed an 8-K on September 30, 2025, reporting an entry into a material definitive agreement and modifications to the rights of secur
• Enzon's Q2 Losses Mount Amid Zero Revenue, Viskase Merger Costs — 10-Q · Aug 14, 2025 Risk: high
  Enzon Pharmaceuticals, Inc. reported a significant decline in financial performance for the three and six months ended June 30, 2025. Total revenues plummeted t
• Enzon Pharmaceuticals Files 8-K: Material Agreement — 8-K · Jun 23, 2025 Risk: medium
  Enzon Pharmaceuticals, Inc. entered into a Material Definitive Agreement on June 20, 2025. The filing also includes Regulation FD Disclosure and Financial State
• Enzon Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 9, 2025 Risk: low
  Enzon Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key financial
• Enzon Pharmaceuticals Files 10-K/A Amendment for Part III Info — 10-K/A · Apr 28, 2025 Risk: low
  Enzon Pharmaceuticals, Inc. is filing an amendment (10-K/A) to its annual report for the year ended December 31, 2024. This amendment, filed on April 28, 2025,
• Enzon Pharmaceuticals Files 8-K: Material Agreement & More — 8-K · Apr 1, 2025 Risk: medium
  On March 31, 2025, Enzon Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also addresses modifications to securit
• Enzon Pharmaceuticals Files 2024 Annual Report — 10-K · Feb 21, 2025 Risk: low
  Enzon Pharmaceuticals, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, incorporated in Delaware and headquartered in Cranford, NJ
• Enzon Pharmaceuticals CFO Departs, New CFO Appointed — 8-K · Jan 10, 2025 Risk: medium
  Enzon Pharmaceuticals, Inc. announced on January 7, 2025, the departure of its Chief Financial Officer, David J. Stack, effective January 10, 2025. The company
• Amneal Pharmaceuticals to Acquire Enzon Pharmaceuticals — 8-K · Dec 27, 2024 Risk: medium
  Enzon Pharmaceuticals, Inc. announced on December 18, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Amneal Pharmaceuti
• Enzon Pharma Files 3Q 2024 10-Q — 10-Q · Nov 5, 2024 Risk: low
  Enzon Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial information and business operations. Key finan
• Enzon Pharmaceuticals 8-K: Shareholder Vote Update — 8-K · Oct 1, 2024 Risk: low
  Enzon Pharmaceuticals, Inc. filed an 8-K on October 1, 2024, reporting on matters submitted to a vote of security holders on September 26, 2024. The filing deta
• Icahn Entities Amend Enzon Pharmaceuticals Stake Filing — SC 13D/A · Aug 19, 2024 Risk: medium
  On August 19, 2024, Carl C. Icahn, through various entities including Icahn Capital LP and Icahn Enterprises L.P., filed an amendment to their Schedule 13D. Thi
• Enzon Pharmaceuticals Files Q2 2024 10-Q Report — 10-Q · Aug 8, 2024 Risk: medium
  Enzon Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial information and operational updates for the second
• Enzon Pharmaceuticals Files 2024 Proxy Statement — DEF 14A · Aug 8, 2024 Risk: low
  Enzon Pharmaceuticals, Inc. filed a definitive proxy statement (DEF 14A) on August 8, 2024, for its annual meeting of stockholders scheduled for September 26, 2
• Enzon Pharmaceuticals Files 8-K/A on Shareholder Nominations — 8-K/A · Jul 11, 2024 Risk: low
  Enzon Pharmaceuticals, Inc. filed an amendment (8-K/A) on July 11, 2024, regarding shareholder nominations for its board of directors. The filing specifically a
• Enzon Pharmaceuticals Files 8-K on Shareholder Nominations — 8-K · Jul 2, 2024 Risk: medium
  Enzon Pharmaceuticals, Inc. filed an 8-K on July 2, 2024, to report on shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing details the comp
• Amneal Pharmaceuticals to Acquire Enzon Pharmaceuticals — 8-K · Jun 14, 2024 Risk: medium
  Enzon Pharmaceuticals, Inc. announced on June 10, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Amneal Pharmaceuticals
• Enzon Pharmaceuticals Enters Material Definitive Agreement — 8-K · May 22, 2024 Risk: medium
  On May 16, 2024, Enzon Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The filing also notes material modifications to the rights of securit
• Enzon Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  ENZON PHARMACEUTICALS, INC. (ENZN) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Enzon Pharmaceuticals, Inc. filed a 10-Q report for the period
• Enzon Pharmaceuticals Files 10-K/A Amendment for Fiscal Year Ended December 31, 2023 — 10-K/A · Apr 26, 2024 Risk: low
  ENZON PHARMACEUTICALS, INC. (ENZN) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Enzon Pharmaceuticals, Inc. filed a 10-K/A (Amendment
• Enzon Pharmaceuticals Files 2023 Annual Report on Form 10-K — 10-K · Mar 20, 2024 Risk: low
  ENZON PHARMACEUTICALS, INC. (ENZN) filed a Annual Report (10-K) with the SEC on March 20, 2024. Enzon Pharmaceuticals, Inc. filed its 10-K report for the fiscal
• ENZON PHARMACEUTICALS Files Administrative 8-K on Dec 31 Event — 8-K · Jan 5, 2024
  ENZON PHARMACEUTICALS, INC. filed an 8-K on January 5, 2024, reporting an 'Other Event' that occurred on December 31, 2023. The filing indicates the company is

Risk Profile

Risk Assessment: Of ENZN's 24 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Viskase Holdings, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $0
• Net Income: $(2.338)M
• EPS: $(0.05)
• Debt-to-Equity: N/A
• Cash Position: $43.256M
• Operating Margin: N/A
• Total Assets: $43.693M
• Total Debt: $0.540M

Key Executives

• David J. Stack
• Michael J. Rossi
• Carl C. Icahn

Industry Context

The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies often pursue mergers and acquisitions to gain access to new technologies, expand product pipelines, or achieve economies of scale. Enzon's strategy to become an acquisition platform aligns with this trend, aiming to leverage its existing structure and potential tax assets.

Top Tags

corporate-governance (5) · corporate-action (5) · amendment (4) · material-agreement (4) · 10-Q (4) · pharmaceuticals (4) · acquisition (3) · filing (3) · financials (3) · 10-K (3)

Key Numbers

• Total Revenues: $0 — for three and nine months ended Sept 30, 2025, indicating no ongoing business operations
• Net Loss: $(824)K — for the three months ended Sept 30, 2025, compared to $254K net income in 2024
• Transaction Expenses: $2.801M — for the nine months ended Sept 30, 2025, driving increased operating losses
• Cash and Cash Equivalents: $43.256M — as of Sept 30, 2025, a decrease from $46.859M at Dec 31, 2024
• Federal NOL Carryforwards: $101M — as of Sept 30, 2025, a potential future tax asset if profitability is achieved
• Common Shares Outstanding: 74,214,603 — as of November 4, 2025, unchanged from December 31, 2024
• Loss per common share: $(0.05) — for the nine months ended Sept 30, 2025, compared to $(0.01) in 2024
• Net Loss (Q2): $(990)K — for Q2 2025, compared to $276K net income in Q2 2024
• Net Loss (YTD): $(1,514)K — for six months ended June 30, 2025, compared to $596K net income in YTD 2024
• Federal NOLs: $101.2M — at June 30, 2025, with $98.1M expiring by 2036
• New Jersey State NOLs: $23.5M — at June 30, 2025
• Reporting Period End Date: 2025-03-31 — Indicates the end of the financial quarter being reported.
• Filing Date: 2025-05-09 — The date the report was officially submitted to the SEC.
• Total Assets: 74,214,603 — Reported for the fiscal year ending 12-31-2024.
• Common Stock Shares: 40,000 — Reported for the fiscal year ending 12-31-2024.

Related Companies

VKS · ENZ

Frequently Asked Questions